Annexon reports Q4 2023 net loss $27.9M; cash $259.7M; Phase 3 GBS data Q2 2024

Annexon, Inc.

Net loss for FY2023 $134.2M vs $141.9M in prior year; R&D spend $113.8M.
Cash and short-term investments $259.7M as of Dec 31, 2023; runway into mid-2026.
Phase 3 ANX005 GBS topline data expected Q2 2024; BLA submission supported by RWE from IGOS.
Phase 3 ANX007 GA ARCHER II trial (sham-controlled) to initiate mid-2024; ARROW head-to-head vs SYFOVRE planned H2 2024.
Completed $125M financing in December 2023 extending operating runway.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Annexon, Inc. reported financial results for fourth quarter and the year ended December 31, 2023.

Period: fourth quarter and the year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 26, 2024, Annexon, Inc. (the “Company”) announced certain financial results for the fourth quarter and the year ended December 31, 2023.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Annexon, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-036399

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.